Manejo clínico de eventos tromboembólicos derivados de complicaciones del COVID-19: revisión integrativa
DOI:
https://doi.org/10.33448/rsd-v10i13.21052Palabras clave:
Tromboembolismo venoso; Embolia pulmonar; COVID-19; Gestión clínica.Resumen
Objetivo: identificar cómo se produce el manejo clínico de los pacientes infectados por COVID-19 que presentan tromboembolismo pulmonar y / o tromboembolismo venoso. Método: Se trata de una revisión integradora, realizada mediante la búsqueda de artículos en las bases de datos BVS, LILACS, MEDLINE, CINAHL Y SCOPUS, con una delimitación temporal de noviembre de 2019 a marzo de 2021. Resultados: Se incluyeron 24 artículos. El diagnóstico se produce a través del dímero D y el fibrinógeno. Para la farmacoterapia se administra heparina de bajo peso molecular (HBPM), 30 mg / 12 h en 12 h para la anticoagulación profiláctica, dosis escalonadas de HBPM con enoxaparina, 0,5 mg / kg dos veces al día para la anticoagulación y rivoxabán 10 mg / día para el postratamiento. anticoagulación. Conclusión: El tratamiento clínico de la TEP y la TEV se produce a través del aumento del dímero D o del fibrinógeno, y la TEP se confirma mediante una angiografía pulmonar. Para la anticoagulación, se usa principalmente HBPM.
Citas
Aryal, M. R., Gosain, R., Donato, A., Pathak, R., Bhatt, V. R., KateL, A. & Kouides, P. (2020). Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment. Current Cardiology Report, 22(52), 01-05.
Atallah, B., Sadik, G. B., Salem, N., Nekidy, W. S. E., Almahmeed, W., Park, W. M. … Mallat, J. (2021). The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients. Anaesthesia, 76, 327–335.
Bikdeli, M. S. D., Madavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E, … Lip, G. Y. H. (2020). COVID-19 e Trombotic ouDoença tromboembólica: Implicaçõespara prevenção, terapia antitrombótica,e Follow-Up. Journal of the American college of cardiology, 75(23), 2950-2973.
Billet, H. H., Reyes-Gil, M., Szymanski, J., Ikemura, K., Stahl, L.R. & Lo, Y. (2020). Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thrombosis and Haemostasis, 120(12), 1691-1699.
BRASIL- Biblioteca Virtual em Saúde (2021). Gerenciamento Clínico. Pesquisa | Portal Regional da BVS (bvsalud.org).
Bozzani, A., Arici, V., Tavazzi, G., Franciscone, M. M., Danesino, V., Rota, M. ... Ragni, F. (2020). Acute arterial and deep venous thromboembolism in COVID-19 patients: Risk factors and personalized therapy. Surgery, 98, 987-992.
Canoglu, K. & Saylan, B. (2020). Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection. ANN SAUDI MED, 462-468.
Ciceri, F., Beretta, L., Scandroglio, A.M., Colombo, S., Landoni, G., Ruggeri, A., Peccatori, J., D’Angelo, A., Cobelli, F., Rovere-Querini, P., Tresoldi, M, Dagna, L. & Zangrillo, A. (2020). Microvascular COVID-19 síndrome tromboinflamatória obstrutiva dos vasos pulmonares (MicroCLOTS): uma hipótese de trabalho da síndrome da angústia respiratória aguda atípica. Crit Care Resusc., 22(02), 95-77.
Creel-Bulos, C., Lui, M., Auld, S. C., Gaddh, M., Kemptom, C. L., Sharipfour, M. … Rangaraju, S. (2020). Trends and diagnostic value of D-dimer levels in patients hospitalized with coronavirus disease 2019. Medicine, 99(46), 01-08.
Cui, S., CheN, S., Li, X., liu, S. & Wang, F. (2020) Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost, 18(6): 1421-24.
Dobesh, P. P. & Trujillo, T. C. (2020). Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. Pharmacoterapy, 40(11),01-53.
Eljilany, I. & Elzouki, A. (2020). D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review. Vascular Health and Risk Management, 16, 455–462.
Fauvel, C., Weizman, O., Trimaille, A., Mika, D., Pommier, T., Pace, N. … Pezel, T. (2020). Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. European Heart Journal, 41(32), 3058-3068.
Fu, Z., Zhuang, X., He, Y., Huang, H & GUO, W. (2020). The diagnostic value of D-dimer with simplified Geneva score (SGS) pre-test in the diagnosis of pulmonary embolism (PE). Journal of Cardiothoracic Surgery, 15(176), 01-07.
Galvão, T. F., Pansani, T. S. A., Harrad, D. (2015). Principais itens para relatar Revisões sistemáticas e Meta-análises: A recomendação PRISMA. Epidemiol. Serv. Saúde, 24(02), 335-342.
Garcia-Olivé, I., Sintes, H., Radua, J., Capa, J.Á. & Rosell, A. (2020). D-dimer in patients infected with COVID-19 and suspected pulmonary embolism. Respiratory Medicine, 169(106023), 01-03.
García-Ortega, A., Oscullo, G., Calvillo, P., MARTÍ-BONMATI, L., MENÉNDEZ, R. & MARTÍNEZ-GARCIA, M.A. (2020). Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection. Journal of infection, 82(02), 261-69.
Gomes, L. M., Marchiori, E. & Rodrigues, R. S. (2006). Trombose venosa profunda e suspeita de tromboembolismo pulmonar: avaliação simultânea por meio de angiotomografia pulmonar e venotomografia combinadas. Radiol Bras, 39(1), 19-26.
Haque, S., Jawed, A., Akhter, N., Dar, S. A., Khan, R. K., MandaL, M. Y. … YahiD, M. (2020). Acetylsalicylic acid (Aspirin): a potent medicine for preventing COVID-19 deaths caused by thrombosis and pulmonary embolism. Eur Rev Med Pharmacol Sci, 24(18),9244-9245.
Klok, F. A., Mos. I. C. M., Nijekeuter. M., Righini, M., Perrier, A. & GaL, L.G. (2008). Simplification of the Revised Geneva Score for Assessing Clinical Probability of Pulmonary Embolism. Arch intern med, 168(19), 2131-36.
Li, M., Gitarts, S., Nyabera, A., Kondaveeti, R., Hammudeh, Y. & Gonzalez, C. (2020). Continuous Infusion Low-Dose Unfractionated Heparin for the Management of Hypercoagulability Associated With COVID-19. Journal of Pharmacy Practice, 20(10), 01-07.
Liao, S., Shao, S., Chen, Y., Chen, Y. & PEndurado M. (2020) Incidence and mortality of pulmonary embolism in COVID-19: a systematic review and meta-analysis. Critical Care, 464(24), 01-05.
Lippi, G., Plebani, M. & Henry, B. M. (2020). A trombocitopenia está associada a infecções graves por coronavírus 2019 (COVID-19): uma meta-análise. Clin Chim Acta, 506, 145-148.
Rossi, F. (2020). Tromboembolismo venoso em pacientes COVID-19. Jornal Vascular Brasileiro, 19, 01-05.
Lodigiani, C., Lapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T. ... Barco, S. (2020). Thrombosis Research,191,9–14.
Long, H., Nie, L., Xiang, X., Li, H., Zhang, X., Fu, X. … Wu, Q. (2020). D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis. BioMed Research International, 01-10.
Manolis, A. S., Manolis, T. A. & Manolis, A. A. (2021). COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management. Journal of Cardiovascular Pharmacology and Therapeutics, 26(1), 12-24.
Marietta, M., Coluccio, V. & Luppi, M. (2020). COVID-19, coagulopatia e tromboembolismo venoso: mais perguntas do que respostas. Estagiário Emerg Med, 12(8), 01-13.
Marinho, F. P., Loyola, I. S., Monteiro, I. O. F., Castro, T. M., Carvalho, M. G. S. ... Santos, G. B. (2021). Inter-relação entre COVID-19 e diabetes mellitus: uma revisão sistemática. Research, Society and Development, 10(2), 01-14.
Mendes, K. D. S., Silveira, R. C. C. P. & Galvão, C. M. (2008). Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto Contexto Enfermagem, 17(4),758-64.
Melnyk, B. M. & Fineout-Overholt, E. (2005). Making the case for evidence-based practice.In: Melnyk BM, Fineout-Overholt E. Evidence-based practice in nursing & healthcare. A guide to best practice. Philadelphia: Lippincot Williams & Wilkins, 3-24.
Mestre-Gómez, B., Lorente-Ramos, R. M., Rogado, J., Franco-Moreno, A., Obispo, B., Salazar-Chiriboga, D. ... Rivas, N. M. (2020). Incidence of pulmonary embolism in non critically ill COVID 19 patients. Predicting factors for a challenging diagnosis. Journal of Thrombosis and Thrombolysis, 51(01), 40-46.
Middeldorp, S., Coppens, M., Haaps, T. F. V., Foppen, M., Vlaar, A. P., Muller, M. C. A., Bouman, C. C. S., Beenen, F. F. M., Kootte, R. S., Heijmans, J., Smits, L. P., Bonta, P. & Es, N. V. (2020). Incidência de tromboembolismo venoso em pacientes hospitalizados com COVID-19. J Thromb Haemost., 18 (08),1995-2002.
Minno, A. D., Ambrosino, P., Calcaterra, I., Minno, M. N. D. D. (2020). COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies. Seminars in Thrombosis & Hemostasis, 46(7), 763-771.
Nadkarni, G. N., Lala, A., Bagiella, E., Chang, H. L., Moreno, P. R. & Pujadas, E. (2020). Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. Journal of the American college of Cardiology, 76 (16),1815-1826.
Nopp, S., Florian, K., Jilma, B., PabingeR, I. & A. Y, C. (2020). Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost, 4(07), 1178–1191.
Ooi, M. Y. X., Rajai, A., Patel, R., Gerova, N., Godhamgaokar, V. & Liong, S. Y. (2020). Pulmonary thromboembolic disease in COVID-19 patients on CT pulmonary angiography – Prevalence, pattern of disease and relationship to D-dimer. Europen jornal of radiology,132(109336), 01-07.
Parks, A. L., Auerbach, A. D., Schinipper, J. L., Anstey, J. E., sterken, D. G., Hecht, T. E. H. & Fang, M. C (2020). COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic. Trombosis Research, 196, 355-358.
Pavoni, V., Gianesello, L., Pazzi, M., Stera, C. & Meconi, T. (2020). Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. Trombosis Research, 196,313-317.
Poulakou, G., Dimakakos, E., Kollias, A., Kyriakoulis, K. G., Rapti, V., Trontzas, I. … Syrigos, K. N. (2021). Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study. In vivo, 35, 653-661.
Rashidi, F., Barco, S., Kamangar, F., Movalled, K., Ghorbani, O., Ansarin, K. ... Ansarin, K. (2021). Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study. Trombosis research, 198,135-38.
Rentsch, C. T., Beckman, J. A., Tomlinson, L., Gellad, W. F., Alcorn, C., Kidway-Khan, F. … Freiberg, M. J. (2021). Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ, 372(31),01-13.
Robert-Ebadi, H., Mostaguir, K., Hovens, M., Kare, M., Verschuren, F., Girard, P., Huisman, M. V. … Gal, G. L. (2017). Acessing clinical probability of pulmonar embolism: prospective validation of the simplified Geneva score. T Tromb Haemost, 15(09), 1764-1769.
Rosovsky, R. P., Grodzin, C., Channick, R., Davis, G. A., Giri, J. S., Horowitz, J. … Rosenfield, K. (2020). Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic. Pulmonary and Cardiovascular: Special Features, 28(6),2590-2601.
Stessel, B., Vanvuchelen, C., Bruckers, L., Herbots, L., RamaekerS, D. & Dubois, J. (2020). Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study Trombosis research, 194, 209-215.
Smith, K., Krajeswki, K. C. & Krajeswiki, M. P. (2020). Practical Considerations in Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19. Am j health-syst pharm, 20(20), 01-07.
Spyropoulos, A. & Weitz, J. I. (2020). Hospitalized COVID-19 patients and venous tromboembolism. Circulation, 142(2),129-132.
Taccone, F. S., Gevenois, P. A., Peluso, L., Pletchette, Z., Lheureux, O., Bresseur, A. ... Vicent, J. (2020). Higher Intensity Thromboprophylaxis Regimens and Pulmonary Embolism in Critically Ill Coronavirus Disease 2019 Patients. Crit Care Med, 48(11), 1087-1090.
Tang, N., Bai, H., Chen, X., Gong, J., Li, D. & Sun, Z. (2020). Anticoagulant Treatment is associated with decreased mortality in severe coronavírus disease 2019 patients with coagulopathy. J trob Haemost, 18,1094-1099.
Trigonis, R. A., Holt, D. B., Yuan, R., Siddiqui, A. A., Craft, M. K., Khan, B. A. … Rahman, O. (2020). Incidence of Venous Thromboembolism in Critically Ill Coronavirus Disease 2019 Patients Receiving Prophylactic Anticoagulation. Critical Care medicine, 98(07), 805-808.
Valle, C., Bonafinni, P. A., Corso, M. D., Vacca, G., Gianatti, A. & Sironi, S. (2020). Association between pulmonary embolism and COVID-19 severe pneumonia: Experience from two centers in the core of the infection Italian peak. European Journal of radiology,137(109613),01-08.
Vernuccio, F., Lombardo, F. P., Cannella, R., Panzuto, F., giambeluca, D., Arzanauskaite, M. ... Cabassa, P. Thromboembolic complications of COVID-19: the combined effect of a pro-coagulant pattern and an endothelial thrombo-inflammatory syndrome. Clinical radiology 2020; 75(11):804-10.
Yang, L., Liu, S., Liu, J., Zhang, Z., Wan, X., Huang, B., Chen, Y. & Zhang, Y. (2020). COVID-19: immunopathogenesis and Immunotherapeutics. Sig Transduct Target Ther, 128(5), 01-08.
Zhai, Z., Li, C., Chen, Y., Gerotziafas, G., Zhang, Z., Whan, J., Liu, P., Elalamy, I. & Whang, C. (2020). Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. J Thromb Haemost., 120(06), 937-48.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2021 Laura Dayane Gois Bispo; Natan Martins Machado; Caio Lopes Pinheiro de Paula; Jussiely Cunha Oliveira; Ingrid Melo Santos; Fernanda Gomes de Magalhães Soares Pinheiro
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores que publican en esta revista concuerdan con los siguientes términos:
1) Los autores mantienen los derechos de autor y conceden a la revista el derecho de primera publicación, con el trabajo simultáneamente licenciado bajo la Licencia Creative Commons Attribution que permite el compartir el trabajo con reconocimiento de la autoría y publicación inicial en esta revista.
2) Los autores tienen autorización para asumir contratos adicionales por separado, para distribución no exclusiva de la versión del trabajo publicada en esta revista (por ejemplo, publicar en repositorio institucional o como capítulo de libro), con reconocimiento de autoría y publicación inicial en esta revista.
3) Los autores tienen permiso y son estimulados a publicar y distribuir su trabajo en línea (por ejemplo, en repositorios institucionales o en su página personal) a cualquier punto antes o durante el proceso editorial, ya que esto puede generar cambios productivos, así como aumentar el impacto y la cita del trabajo publicado.
